Related Experiment Videos

Comparison of a chronotherapeutically administered beta blocker vs. a traditionally administered beta blocker in

Joel M Neutel1, Keith Rotenberg

  • 1Orange County Research Center, Tustin, CA 92780, USA. jmneutel@aol.com

Insights

Delayed-release propranolol (INP) taken at night reduced cardiac workload more effectively in sensitive patients than traditional morning dosing (ILA). This chronotherapeutic approach improves morning cardiovascular control in hypertension.

Area of Science:

  • Cardiology
  • Pharmacology
  • Chronobiology

Background:

  • Morning increases in blood pressure and heart rate elevate myocardial oxygen demand.
  • Beta blockers can mitigate cardiac workload, especially in sensitive individuals.

Purpose of the Study:

  • To evaluate the impact of a novel chronotherapeutic beta blocker on hypertensive patients.
  • To compare delayed-release propranolol (INP) taken at bedtime with immediate-release propranolol (ILA) taken in the morning.

Main Methods:

  • 44 hypertensive patients received INP and ILA formulations for 4 weeks each in a crossover design.
  • Thirty-four-hour ambulatory blood pressure monitoring and pharmacokinetic analyses were performed.
  • Subgroup analysis focused on the top 25% of propranolol responders (beta-blocker sensitive patients).

Main Results:

  • Both INP and ILA significantly reduced 24-hour blood pressure.
  • INP demonstrated a greater reduction in double product (heart rate x systolic blood pressure) between 6 a.m. and noon in beta-blocker sensitive patients compared to ILA.
  • Sensitive patients on INP showed greater reductions in blood pressure and heart rate during morning hours.

Conclusions:

  • Both INP and ILA are effective once-daily beta blockers.
  • Delayed-release propranolol administered at bedtime offers superior morning cardiovascular protection in beta-blocker sensitive hypertensive patients.

Related Concept Videos

Antihypertensive Drugs: Types of β-Blockers01:28

Antihypertensive Drugs: Types of β-Blockers

β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and vasodilation. This widens airways and...
Adrenergic Antagonists: ɑ and β-Receptor Blockers01:31

Adrenergic Antagonists: ɑ and β-Receptor Blockers

Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is clinically...
Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers01:27

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in bronchial smooth...
Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers01:25

Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers

β-adrenergic antagonists, or β-blockers, modulate the sympathetic nervous system by targeting β-adrenoceptors and inhibiting catecholamine-mediated sympathetic responses. β-blockers differ in their adrenoceptor subtype affinity, lipophilicity, and α-blocking capabilities. The history of β-blocker development began with the prototype, dichloroisoprenaline, which exhibited partial agonist activity. As a result, propranolol was developed as a pure antagonist but nonselective agent, paving the way...
Antihypertensive Drugs: Action of β1 Blockers01:17

Antihypertensive Drugs: Action of β1 Blockers

β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this, β1-blockers...
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...